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Introduction

Results

➢ Cancer cells release biological material
into extracellular vesicles (EVs).
➢ Extracellular vesicles are defined as
membrane-coated vesicles that vary in
size. According to their size, there are
small extracellular vesicles (sEVs)
between 50 and 150 nm in diameter,
and medium-large EVs (mlEVs)
between 160-300 nm in diameter (ref)
➢ Both sEVs and mlEVs have been
successfully isolated from biological
fluids, such as blood, urine, or ascites
(ref)
➢ Cancer cells-derived EVs have been
investigated for their possible role as
cancer biomarkers, particularly as
early diagnostic markers or as
predictive markers of response to
therapy
➢ EVs may be a predictive marker of
response to PARP inhibitors, a specific
targeted treatment for ovarian cancer

➢ We isolated EVs from a sensitive
and a resistant cell line to PARPi
and identified them via
nanotracking
➢ We studied the EVs content with
flow cytometry to measure their
content in PARP and DNA
➢ Sensitive cells to PARPi have an
increase in PARP-DNA
complexes after PARPi
treatment, as compared to
resistant cells

Conclusions
➢ We are currently assessing the
differences in cargo of EVs from
cells sensitive and resistant to
PARP inhibitors through flow
cytometry, western blot, and
confocal imaging
➢ Further analysis will be
performed on circulating EVs
from in vivo models and patients
affected by ovarian cancer who
underwent treatment with PARP
inhibitors

Aims
➢ To isolate and analyze EVs
secreted from ovarian cancer cells
with higher or lower sensitivity to
PARP inhibitors
➢ To analyze EVs with the gold
standard techniques (nanotracking)
and transmission electron
microscopy (TEM)

Results
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Methods
➢ EV Isolation:
1. Collect conditioned medium from
cancer cells
2. Remove cells, dead cells, and
cellular debris
3. Collect miEVs via
ultracentrifugation at 10,000 X g
for 40 minutes
4. Wash and resuspend miEVs in
filtered PBS
5. Collect sEVs via ultracentrifugation
at 100,000 X g for 120 minutes
6. Wash and resuspend sEVs in
filtered PBS
➢ EV Analysis:
1. Resuspend 10 uL of isolated EVs
in 1 ml of filtered PBS
2. Load the sample into a 1 ml
syringe and analyze at NanoSight
3. Resuspend EVs pellet in TEM
buffer to undergo microscopy
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